Renaissance Technologies
APRE icon

Renaissance Technologies’s Aprea Therapeutics APRE Stock Holding History

Renaissance Technologies’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$84.9K Buy
105,800
+80,700
+322% +$67.3K ﹤0.01% 2996
2026
Q1 		$19.1K Buy
+25,100
New +$19.7K ﹤0.01% 3173
2023
Q1 		– Sell
-8,960
Closed -$59K – 3958
2022
Q4 		$59K Sell
8,960
-5,167
-37% -$54.5K ﹤0.01% 3765
2022
Q3 		$184K Sell
14,127
-1,461
-9% -$25.9K ﹤0.01% 3410
2022
Q2 		$234K Buy
15,588
+693
+5% +$16K ﹤0.01% 3577
2022
Q1 		$554K Buy
14,895
+799
+6% +$32.7K ﹤0.01% 3121
2021
Q4 		$809K Buy
+14,096
New +$1.25M ﹤0.01% 2802

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Renaissance Technologies's APRE Position: Q2 2026 in Review

Renaissance Technologies increased its Aprea Therapeutics (APRE) stake by 322% in Q2 2026, buying an estimated $67.3K and bringing the position to 105,800 shares worth $84.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2996.

Renaissance Technologies first reported a position in APRE in Q4 2021 and has held it in 7 quarters since. The position peaked at $809K in Q4 2021. 28 funds tracked by Wall St. Rank hold APRE as of Q2 2026.

  • Renaissance Technologies held 105,800 shares of Aprea Therapeutics worth $84.9K as of Q2 2026.
  • Renaissance Technologies bought 80,700 Aprea Therapeutics shares in Q2 2026, an estimated $67.3K.
  • Aprea Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2996 holding.
  • Renaissance Technologies first reported a position in Aprea Therapeutics in Q4 2021 and has held it in 7 quarters since.
  • Renaissance Technologies's Aprea Therapeutics position peaked at $809K in Q4 2021.
  • 28 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.